Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

NCT03076372 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT03076372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03076372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
February 22, 2017
Completion date
December 31, 2018
Enrollment
34 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial carcinoma, gastric carcinoma, non-small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, prostate adenocarcinoma, small cell lung cancer, soft tissue sarcoma, solid tumors, squamous cell carcinoma of the head and neck, triple negative breast cancer, urothelial carcinoma